Abstract 29P
Background
Comprehensive genomic testing is not considered standard of care for patients with small cell lung cancer (SCLC), as no molecular targeted therapies have been approved. Currently there is limited data on the clinical impact of molecular co-alterations in SCLC.
Methods
Patients with extensive-stage SCLC undergoing panel sequencing at initial diagnosis were enrolled in the study between December 1st, 2022, and December 1st, 2024. The panel sequencing was based on the examination of 324 genes and the introns of 34 genes known to be involved in rearrangements. Clinical data, including overall survival (OS) and real-world progression-free survival (rwPFS) to different treatment lines, were retrospectively assessed. Multivariate Cox regression models included patient characteristics, specific two-way interactions, OS, TMB, PD-L1 status, and molecular co-alterations detected by next-generation sequencing.
Results
A total of 29 patients with SCLC were analyzed, 18 (62%) males with a median age of 62 years (range: 41-78). Further molecular subgroups were classified based on their genomic co-alteration profile: 5 (17%) patients with NOTCH1/RB1/TP53 co-mutations, 4 (14%) patients with CREBBP/RB1/TP53 and 4 (14%) patients with PTEN/RB1/TP53 co-mutations. Median overall survival (mOS) was shortest in patients with CREBBP/RB1/TP53 at 3 months (ms) followed by patients with PTEN/RB1/TP53 with an mOS of 9 ms. The mOS across all enrolled patients was 14ms. The rwPFS to first-line treatment (rwPFS-1) was shortest in the PTEN/RB1/TP53 subgroup at 5.5 ms followed by 6 ms in both the NOTCH1/RB1/TP53 and CREBBP/RB1/TP53 subgroups. rwPFS-2 was 4.5 ms across all three subgroups.
Conclusions
Patients with co-alterations in any of the three genes PTEN, NOTCH1, or CREBBP to RB1 or TP53 showed inferior median overall survival (mOS), underlining that these co-alterations are poor risk factors associated with a dismal prognosis. Our findings based on real-world data indicate that the use of panel sequencing in extensive-stage SCLC patients identifies co-mutated subgroups associated with therapy resistance to current standard treatments and highlights the unmet need for targeted therapeutic strategies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
132P - Deciphering aggressive behavior in uterine inflammatory myofibroblastic tumors: Clinicopathological and molecular analysis
Presenter: Nikola Hajkova
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Exploring genomic instability at the single-cell level using a new method for the inference of copy number alterations
Presenter: Lucrezia Patruno
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - SPICE: Probabilistic reconstruction of copy-number evolution in cancer
Presenter: Abigail Bunkum
Session: Cocktail & Poster Display session
Resources:
Abstract
135P - Revealing the third kind of pathway of colorectal cancer developing from laterally spreading tumors
Presenter: Jianshe Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Investigating the evolutionary and regulatory dynamics of acquired resistance to BTK inhibitors in activated B-cell diffuse large B-cell lymphoma cells
Presenter: Luminita Ruje
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Analysis of master regulatory transcription factors and their associated transcriptomic profiles in SCLC patients
Presenter: Janik Riese
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Rewiring of cis-regulatory and kinase signalling networks in acalabrutinib-resistant ABC DLBCL cells
Presenter: Pavel Artemov
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - An unconditionally dynamic culture system for cancer stem cell
Presenter: Ya-Juan Zhu
Session: Cocktail & Poster Display session
Resources:
Abstract